Affiliation:
1. College of Pharmacy Dalhousie University Halifax Nova Scotia Canada
2. Division of Research Kaiser Permanente Pleasanton California USA
Abstract
The diagnostic workup following a positive prostate‐specific antigen test may lead to significant out‐of‐pocket costs for patients. Providers should incorporate costs into shared decision‐making with patients; in parallel, policymakers and payers must identify solutions to mitigate financial burdens that risk widening existing disparities in prostate cancer care.